{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:32:07Z","timestamp":1778837527892,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00277-019-03667-1","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T16:05:04Z","timestamp":1555344304000},"page":"1657-1664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma"],"prefix":"10.1007","volume":"98","author":[{"given":"Jaewon","family":"Hyung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-sik","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Sook","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jooryung","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-4431","authenticated-orcid":false,"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"3667_CR1","first-page":"17","volume":"32","author":"RV Lukas","year":"2018","unstructured":"Lukas RV, Stupp R, Gondi V, Raizer JJ (2018) Primary central nervous system lymphoma-part 1: epidemiology, diagnosis, staging, and prognosis. Oncology (Williston Park) 32:17\u201322","journal-title":"Oncology (Williston Park)"},{"key":"3667_CR2","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/bjc.2011.357","volume":"105","author":"JL Villano","year":"2011","unstructured":"Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105:1414\u20131418. \n                    https:\/\/doi.org\/10.1038\/bjc.2011.357","journal-title":"Br J Cancer"},{"key":"3667_CR3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ajh.23551","volume":"88","author":"BP O\u2019Neill","year":"2013","unstructured":"O\u2019Neill BP, Decker PA, Tieu C, Cerhan JR (2013) The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin\u2019s lymphoma. Am J Hematol 88:997\u20131000. \n                    https:\/\/doi.org\/10.1002\/ajh.23551","journal-title":"Am J Hematol"},{"key":"3667_CR4","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35:2410\u20132418. \n                    https:\/\/doi.org\/10.1200\/jco.2017.72.7602","journal-title":"J Clin Oncol"},{"key":"3667_CR5","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Ros\u00e9e PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rud\u00e0 R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, G\u00f8rl\u00f8v JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG) (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217\u2013e227. \n                    https:\/\/doi.org\/10.1016\/s2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"key":"3667_CR6","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, R\u00f6th A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leith\u00e4user M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, N\u00e4gele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036\u20131047. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(10)70229-1","journal-title":"Lancet Oncol"},{"key":"3667_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","volume":"38","author":"P Colombat","year":"2006","unstructured":"Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Bro\u00ebt S, Linassier C, Lamy T (2006) High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 38:417\u2013420. \n                    https:\/\/doi.org\/10.1038\/sj.bmt.1705452","journal-title":"Bone Marrow Transplant"},{"key":"3667_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/annonc\/mdl458","volume":"18","author":"M Montemurro","year":"2007","unstructured":"Montemurro M, Kiefer T, Schuler F, al-Ali H, Wolf HH, Herbst R, Haas A, Helke K, Theilig A, Lotze C, Hirt C, Niederwieser D, Schwenke M, Kruger W, Dolken G, For the Ostdeutsche Studiengruppe Hamatologie und Onkologie (2007) Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan\/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 18:665\u2013671. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdl458","journal-title":"Ann Oncol"},{"key":"3667_CR9","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","volume":"24","author":"G Illerhaus","year":"2006","unstructured":"Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24:3865\u20133870. \n                    https:\/\/doi.org\/10.1200\/jco.2006.06.2117","journal-title":"J Clin Oncol"},{"key":"3667_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.leukres.2010.07.016","volume":"35","author":"JE Kim","year":"2011","unstructured":"Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, Park CJ, Huh J, Suh C (2011) BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 35:183\u2013187. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2010.07.016","journal-title":"Leuk Res"},{"key":"3667_CR11","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","volume":"21","author":"LE Abrey","year":"2003","unstructured":"Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21:4151\u20134156. \n                    https:\/\/doi.org\/10.1200\/jco.2003.05.024","journal-title":"J Clin Oncol"},{"key":"3667_CR12","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis L, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F, International Primary CNS Lymphoma Collaborative Group (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034\u20135043. \n                    https:\/\/doi.org\/10.1200\/jco.2005.13.524","journal-title":"J Clin Oncol"},{"key":"3667_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0038-1627470","volume":"38","author":"S Low","year":"2018","unstructured":"Low S, Batchelor TT (2018) Primary central nervous system lymphoma. Semin Neurol 38:86\u201394. \n                    https:\/\/doi.org\/10.1055\/s-0038-1627470","journal-title":"Semin Neurol"},{"key":"3667_CR14","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","volume":"127","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Illerhaus G (2016) The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood 127:1642\u20131649. \n                    https:\/\/doi.org\/10.1182\/blood-2015-10-636340","journal-title":"Blood"},{"key":"3667_CR15","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1002\/cncr.30695","volume":"123","author":"Z DeFilipp","year":"2017","unstructured":"DeFilipp Z, Li S, El-Jawahri A et al (2017) High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer 123:3073\u20133079. \n                    https:\/\/doi.org\/10.1002\/cncr.30695","journal-title":"Cancer"},{"key":"3667_CR16","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM et al (2015) R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125:1403\u20131410. \n                    https:\/\/doi.org\/10.1182\/blood-2014-10-604561","journal-title":"Blood"},{"key":"3667_CR17","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, la Ros\u00e9e P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, S\u00f8nderskov G\u00f8rl\u00f8v J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG) (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol 4:e510\u2013e523. \n                    https:\/\/doi.org\/10.1016\/s2352-3026(17)30174-6","journal-title":"Lancet Haematol"},{"key":"3667_CR18","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1016\/S2352-3026(16)30050-3","volume":"3","author":"G Illerhaus","year":"2016","unstructured":"Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf HH, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, M\u00f6hle R, R\u00f6th A, Pfreundschuh M, von Baumgarten L, Deckert M, Hader C, Fricker H, Valk E, Schorb E, Fritsch K, Finke J (2016) High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 3:e388\u2013e397. \n                    https:\/\/doi.org\/10.1016\/s2352-3026(16)30050-3","journal-title":"Lancet Haematol"},{"key":"3667_CR19","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","volume":"25","author":"LL Muldoon","year":"2007","unstructured":"Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM, Neuwelt EA (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295\u20132305. \n                    https:\/\/doi.org\/10.1200\/jco.2006.09.9861","journal-title":"J Clin Oncol"},{"key":"3667_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2165\/00003088-200645090-00002","volume":"45","author":"S Motl","year":"2006","unstructured":"Motl S, Zhuang Y, Waters CM, Stewart CF (2006) Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 45:871\u2013903. \n                    https:\/\/doi.org\/10.2165\/00003088-200645090-00002","journal-title":"Clin Pharmacokinet"},{"key":"3667_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/1040-8428(92)90092-5","volume":"13","author":"VJ Wiebe","year":"1992","unstructured":"Wiebe VJ, Smith BR, DeGregorio MW, Rappeport JM (1992) Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 13:241\u2013270","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03667-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03667-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03667-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T23:11:00Z","timestamp":1586819460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03667-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3667"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03667-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,15]]},"assertion":[{"value":"10 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required (IRB 2018-1275).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}